- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
Monte Rosa Therapeutics is a biotechnology business based in the US. Monte Rosa Therapeutics shares (GLUE) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.89 – a decrease of 10.28% over the previous week. Monte Rosa Therapeutics employs 129 staff and has a trailing 12-month revenue of around $5.8 million.
Our top picks for where to buy Monte Rosa Therapeutics stock
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Monte Rosa Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – GLUE. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Monte Rosa Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Monte Rosa Therapeutics stock price (NASDAQ: GLUE)
Use our graph to track the performance of GLUE stocks over time.Monte Rosa Therapeutics shares at a glance
Information last updated 2024-10-25.
| Latest market close | $4.89 |
|---|---|
| 52-week range | $2.77 - $8.84 |
| 50-day moving average | $5.62 |
| 200-day moving average | $5.31 |
| Wall St. target price | $15.83 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.22 |
Is it a good time to buy Monte Rosa Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Monte Rosa Therapeutics price performance over time
Historical closes compared with the close of $4.89 from 2024-10-25
| 1 week (2024-10-21) | -10.28% |
|---|---|
| 1 month (2024-09-27) | -5.42% |
| 3 months (2024-07-26) | 4.71% |
| 6 months (2024-04-26) | -8.26% |
| 1 year (2023-10-27) | 75.90% |
|---|---|
| 2 years (2022-10-28) | -43.66% |
| 3 years (2021-10-28) | 27.15 |
| 5 years (2019-10-24) | N/A |
Monte Rosa Therapeutics financials
| Revenue TTM | $5.8 million |
|---|---|
| Gross profit TTM | $0 |
| Return on assets TTM | -27.99% |
| Return on equity TTM | -59.51% |
| Profit margin | 0% |
| Book value | $3.66 |
| Market Capitalization | $298.9 million |
TTM: trailing 12 months
Monte Rosa Therapeutics share dividends
We're not expecting Monte Rosa Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
Monte Rosa Therapeutics share price volatility
Over the last 12 months, Monte Rosa Therapeutics's shares have ranged in value from as little as $2.765 up to $8.84. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Monte Rosa Therapeutics's is 1.424. This would suggest that Monte Rosa Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Monte Rosa Therapeutics's beta into context you can compare it against those of similar companies.
- Trillium Therapeutics (TRIL.US): 1.9046
- Surface Oncology (SURF.US): 1.7527
- Mersana Therapeutics (MRSN.US): 1.472
Monte Rosa Therapeutics overview
Monte Rosa Therapeutics, Inc. , a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts. .
Frequently asked questions
What percentage of Monte Rosa Therapeutics is owned by insiders or institutions?Currently 0.706% of Monte Rosa Therapeutics shares are held by insiders and 86.748% by institutions. How many people work for Monte Rosa Therapeutics?
Latest data suggests 129 work at Monte Rosa Therapeutics. When does the fiscal year end for Monte Rosa Therapeutics?
Monte Rosa Therapeutics's fiscal year ends in December. Where is Monte Rosa Therapeutics based?
Monte Rosa Therapeutics's address is: 321 Harrison Avenue, Boston, MA, United States, 02118 What is Monte Rosa Therapeutics's ISIN number?
Monte Rosa Therapeutics's international securities identification number is: US61225M1027
More resources on Finder
More guides on Finder
-
Best broker cash sweep rates of 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for Beginners: 9 Best Trading Platforms to Get Started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
SoFi Invest vs. Robinhood
Compare pros, cons, research tools and reviews for these two trading platforms.
-
10 Best Stock Apps of 2024 to Elevate Your Mobile Trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
10 Best Brokerage Accounts for Trading and Investing in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
SoFi Invest® review 2024: Simple investing, free CFP access
SoFi Invest is a commission-free platform with both active and automated investment accounts.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
How to Invest $20K: 8 Ways to Maximize Earnings
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
-
Robinhood Review 2024: IRA Match and No Commissions
A deep dive into the highlights and limitations of Robinhood.
Ask a question